Rabeprazole Specific Clinical Experience Investigation for the Long-term Combination Therapy With Low-dose Aspirin

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02423187

Enrollment

1568

Registered

2015-04-22

Start date

2015-03-17

Completion date

2017-10-30

Last updated

2018-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duodenal Ulcer, Gastric Ulcer

Keywords

Stomach ulcer, Duodenal ulcer, Rabeprazole, Recurrence

Brief summary

To investigate the safety and efficacy of long-term combination therapy with rabeprazole and low-dose aspirin.

Interventions

OTHERNo Intervention

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. Patients taking long-term low-dose aspirin for prevention of thrombus/embolism at the start of administration of rabeprazole (including patients who start low-dose aspirin on the same day as the start of administration of rabeprazole). 2. Patients with a history of gastric/duodenal ulcers. 3. Patients requiring long-term use of rabeprazole for prevention of recurrence of gastric/duodenal ulcers induced by low-dose aspirin.

Exclusion criteria

1. Patients with gastric/duodenal ulcers at the start of administration of rabeprazole. 2. Patients with active upper gastrointestinal bleeding at the start of administration of rabeprazole. 3. Patients with contraindication for rabeprazole.

Design outcomes

Primary

Measure	Time frame
Incidence of adverse drug reactions	52 weeks

Secondary

Measure	Time frame
Recurrence rate of peptic ulcer	52 weeks

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026